The use of long-acting antiretroviral regimens will not be suitable for all people living with HIV for various reasons (previous virological failure with drugs of the same class, side effects, logistic difficulties, and costs). We think that short-cycle therapies could represent a feasible and valuable option for antiretroviral treatment optimization in selected individuals. So here we review clinical evidence about efficacy of short-cycle therapy in suppressed HIV-infected patients.
Short Cycle, Intermittent Therapy: A Valuable Option in Selected, Virologically Suppressed People Living with HIV / Lanzafame, Massimiliano; Lattuada, Emanuela; Luise, Dora; Delama, Andrea; Fait, Daniela; Vento, Sandro. - In: AIDS RESEARCH AND HUMAN RETROVIRUSES. - ISSN 0889-2229. - 40:2(2024), pp. 69-72. [10.1089/AID.2022.0168]
Short Cycle, Intermittent Therapy: A Valuable Option in Selected, Virologically Suppressed People Living with HIV
Lanzafame, Massimiliano;
2024-01-01
Abstract
The use of long-acting antiretroviral regimens will not be suitable for all people living with HIV for various reasons (previous virological failure with drugs of the same class, side effects, logistic difficulties, and costs). We think that short-cycle therapies could represent a feasible and valuable option for antiretroviral treatment optimization in selected individuals. So here we review clinical evidence about efficacy of short-cycle therapy in suppressed HIV-infected patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
AIDS Res Hum Retroviruses 2024.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
634.66 kB
Formato
Adobe PDF
|
634.66 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
